Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · IEX Real-Time Price · USD
10.25
-0.17 (-1.63%)
At close: Jul 19, 2024, 4:00 PM
10.26
+0.01 (0.10%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $236.15M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $50.79M with 8.24% year-over-year growth. In the year 2023, Dynavax Technologies had annual revenue of $232.28M.
Revenue (ttm)
$236.15M
Revenue Growth
-63.98%
P/S Ratio
5.68
Revenue / Employee
$578,797
Employees
408
Market Cap
1.34B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 392.89M | 844.00% |
Dec 31, 2020 | 46.55M | 11.33M | 32.18% |
Dec 31, 2019 | 35.22M | 27.02M | 329.60% |
Dec 31, 2018 | 8.20M | 7.87M | 2,407.03% |
Dec 31, 2017 | 327.00K | -10.72M | -97.04% |
Dec 31, 2016 | 11.04M | 6.99M | 172.67% |
Dec 31, 2015 | 4.05M | -6.98M | -63.29% |
Dec 31, 2014 | 11.03M | -219.00K | -1.95% |
Dec 31, 2013 | 11.25M | 1.54M | 15.82% |
Dec 31, 2012 | 9.71M | -11.90M | -55.06% |
Dec 31, 2011 | 21.61M | -2.34M | -9.75% |
Dec 31, 2010 | 23.95M | -16.37M | -40.60% |
Dec 31, 2009 | 40.32M | 3.22M | 8.69% |
Dec 31, 2008 | 37.09M | 23.00M | 163.21% |
Dec 31, 2007 | 14.09M | 9.25M | 190.76% |
Dec 31, 2006 | 4.85M | -9.81M | -66.93% |
Dec 31, 2005 | 14.66M | -157.00K | -1.06% |
Dec 31, 2004 | 14.81M | 13.99M | 1,693.22% |
Dec 31, 2003 | 826.00K | -601.00K | -42.12% |
Dec 31, 2002 | 1.43M | -932.00K | -39.51% |
Dec 21, 2001 | 2.36M | 305.00K | 14.85% |
Dec 31, 2000 | 2.05M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.25B |
U.S. Physical Therapy | 611.97M |
ANI Pharmaceuticals | 517.46M |
Phreesia | 373.67M |
Arcus Biosciences | 237.00M |
Vir Biotechnology | 79.60M |
Nurix Therapeutics | 62.30M |
DVAX News
- 24 days ago - Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program - PRNewsWire
- 7 weeks ago - Dynavax to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine - Reuters
- 2 months ago - Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S. - PRNewsWire
- 2 months ago - Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates - PRNewsWire
- 3 months ago - Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - PRNewsWire
- 5 months ago - Dynavax to Present at TD Cowen's 44th Annual Health Care Conference - PRNewsWire
- 5 months ago - Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance - PRNewsWire